Evidence map›Paper›PMID 34326837›Full record

ArticleFrontiers in immunology2021

PSGL-1 Is a T Cell Intrinsic Inhibitor That Regulates Effector and Memory Differentiation and Responses During Viral Infection.

Roberto Tinoco, Emily N Neubert, Christopher J Stairiker, Monique L Henriquez, Linda M Bradley

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. P-Selectin Glycoprotein Ligand (PSGL)-1 Expression on CD4Pathogens (Basel, Switzerland) · 2025
    Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Themis suppresses the effector function of CD8Cellular & molecular immunology · 2023
    Article
  10. Review
  11. scDual-Seq ofFrontiers in immunology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Roberto TinocoDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, United States.
Emily N NeubertDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, United States.
Christopher J StairikerInfectious and Inflammatory Disease Center, NCI Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
Monique L HenriquezDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, United States.
Linda M BradleyInfectious and Inflammatory Disease Center, NCI Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
University of California, Irvine · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
Virus-host interactions: a multi-scale training programT32AI007319 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SEMLER, BERT L, SHI, YONGSHENG · 1988 to 2024
$2.4M
PSGL-1 mechanisms of T cell exhaustionR01AI137239 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI TINOCO, ROBERTO · 2019 to 2024
$2.1M
Regulation of Chronic Viral InfectionsR01AI106895 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI BRADLEY, LINDA MAC PHERSON · 2014 to 2017
$1.9M
NCI NIH HHS P30 CA030199NIAID NIH HHS R01 AI106895NIAID NIH HHS R01 AI137239NIAID NIH HHS T32 AI007319
6 · The paper itself

Abstract

Effective T cell differentiation during acute virus infections leads to the generation of effector T cells that mediate viral clearance, as well as memory T cells that confer protection against subsequent reinfection. While inhibitory immune checkpoints have been shown to promote T cell dysfunction during chronic virus infections and in tumors, their roles in fine tuning the differentiation and responses of effector and memory T cells are only just beginning to be appreciated. We previously identified PSGL-1 as a fundamental regulator of T cell exhaustion that sustains expression of several inhibitory receptors, including PD-1. We now show that PSGL-1 can restrict the magnitude of effector T cell responses and memory T cell development to acute LCMV virus infection by limiting survival, sustaining PD-1 expression, and reducing effector responses. After infection, PSGL-1-deficient effector T cells accumulated to a greater extent than wild type T cells, and preferentially generated memory precursor cells that displayed enhanced accumulation and functional capacity in response to TCR stimulation as persisting memory cells. Although, PSGL-1-deficient memory cells did not exhibit inherent greater sensitivity to cell death, they failed to respond to a homologous virus challenge after adoptive transfer into naïve hosts indicating an impaired capacity to generate memory effector T cell responses in the context of viral infection. These studies underscore the function of PSGL-1 as a key negative regulator of effector and memory T cell differentiation and suggest that PSGL-1 may limit excessive stimulation of memory T cells during acute viral infection.

Indexed as

Adoptive TransferAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell DifferentiationImmunologic MemoryLymphocyte ActivationLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMembrane GlycoproteinsMiceMice, Inbred C57BLMice, KnockoutTreatment OutcomeMembrane GlycoproteinsP-selectin ligand proteineffector T cellsLCMVmemory T cellsPSGL-1virus infection

Identifiers

PMID34326837
PMCPMC8314012
OpenAlexW3181087071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.